The company is experiencing rapid expansion of business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of manufacturing capacity and pre-commercial preparations. In April 2025, the company closed a $36.9 million offering and intends to use proceeds for general corporate purposes, including R&D, manufacturing expansion, and potential commercialization of product candidates.
Cyborg Score Rationale
Alpha Tau demonstrates strong clinical momentum with multiple FDA-approved trials and recent $36.9M funding from strategic partner Oramed. However, as a clinical-stage company with significant losses and limited commercialization experience, execution risk remains material.
Top Insights
Four active U.S. trial approvals including expansion into multiple internal organs and manufacturing scale-up underway
Secured $36.9 million in funding from Oramed Pharmaceuticals in April 2025
Proprietary Alpha DaRT technology with intratumoral radium-224 delivery designed to spare healthy tissue around tumors
Technology originated at Tel Aviv University with backing from academic inventors providing strong intellectual foundation
Named Competitors
Conventional Radiotherapy Systems — External beam and traditional brachytherapy platforms
Targeted Cancer Therapeutics — Immunotherapy and targeted small molecule approaches
Recent Developments
(April 2025) Closed $36.9M registered direct offering with Oramed Pharmaceuticals strategic investment
(August 2025) FDA approval of IDE for U.S. pilot study in recurrent glioblastoma multiforme
(Multiple 2025) Announced Q2 2025 financial results with multiple U.S. trial updates
Open the full interactive Alpha Tau Medical Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.